Insulin aspart 30 injection held the largest market share among diabetic drug products in China in 2021 at 18.2%. Following closely, Insulin glargine injection and recombinant glargine injection held 17.4% and 12.2% respectively. In 2021, diabetes affected about one out of every ten COVID-19 patients in China, and according to the WHO, 20% of people with diabetes and diabetes-related disorders died in China in January 2020 as a result of COVID-19.